TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37283943
Drug: Anti-SARS-CoV-2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-SARS-CoV-2 antibodies tested at baseline, 8 weeks, and 16 weeks.
Study: 37283969
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL (135 μg) candidate vaccine
Study: 37283969
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL (270 μg) candidate vaccine
Study: 37283969
Drug: Candidate vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate vaccine (both dosages)
Study: 37283977
Drug: LLDT-8 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLDT-8 0.5 mg daily
Study: 37283977
Drug: LLDT-8 1
Normalized name: LLDT-8
DrugBank: PG-701 (DB12252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLDT-8 1 mg daily
Study: 37284847
Drug: NK-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV)
Study: 37284847
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no NK-1 receptor antagonist)
Study: 37285081
Drug: Tirzepatide 2.5-10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 2.5-10.0 mg
Study: 37285081
Drug: Tirzepatide 2.5-15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 2.5-15.0 mg
Study: 37285113
Drug: MOTS-c peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOTS-c peptide treatment
Study: 37285278
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once daily (o.d.)
Study: 37285718
Drug: Eribulin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin monotherapy
Study: 37285801
Drug: Cholecalciferol OTF
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol OTF strips (40,000 IU) administered for 12 weeks
Study: 37285865
Drug: Talazoparib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib plus enzalutamide (talazoparib 0.5 mg + enzalutamide 160 mg)
Study: 37285865
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus enzalutamide (placebo + enzalutamide 160 mg)
Study: 37285925
Drug: Lotilaner ophthalmic
Normalized name: lotilaner ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner ophthalmic solution 0.25%
Study: 37286048
Drug: 1 intravenous
Normalized name: Choline C 11 Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 intravenous dose of 24 mg dexamethasone (DX1)
Study: 37286048
Drug: 2 intravenous
Normalized name: Rubidium Chloride Rb 82 Intravenous Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 intravenous doses of 24 mg dexamethasone (DX2)
Study: 37286215
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine (M-M-R VaxPro)
Study: 37286303
Drug: Tebentafusp (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebentafusp (alone or in combination)
Study: 37286303
Drug: Tebentafusp with
Normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tebentafusp with checkpoint inhibitors
Study: 37286312
Drug: Intravesical recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical recombinant BCG (rBCG: VPM1002BC) applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin/gemcitabine every 3 weeks.
Study: 37286312
Drug: Atezolizumab 1200 mg
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg every 3 weeks started together with rBCG and given for four cycles, continued as maintenance therapy after surgery every 3 weeks for 13 cycles.
Study: 37286319
Drug: Treatment-as-usual (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (standard care) for mothers after CS.
Study: 37286324
Drug: mFOLFIRINOX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX treatment with circadian-based telemonitoring-telecare platform
Study: 37286324
Drug: mFOLFIRINOX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFIRINOX treatment
Study: 37286457
Drug: Radioligand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand treatment
Study: 37286557
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg every 3 weeks in cohort A (HER2-positive, IHC 3+ or IHC 2+/ISH+).
Study: 37287080
Drug: Current glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current glucocorticoid (GC) treatment
Study: 37287080
Drug: Cumulative GC
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative GC dose and duration of use
Study: 37287970
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg methylprednisolone intravenously for 3 consecutive days followed by tocilizumab (TCZ) monotherapy
Study: 37288326
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion group
Study: 37288326
Drug: 2-hour infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-hour infusion group
Study: 37288570
Drug: All medication
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All medication class regimens
Study: 37288570
Drug: 4 or
Normalized name: Dex4 Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 or more medication classes
Study: 37288582
Drug: Neoadjuvant immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunochemotherapy (NAICT) with toripalimab (PD-1 inhibitor) and albumin paclitaxel/cisplatin (TTP)
Study: 37289256
Drug: Geptanolimab (GB226)
Normalized name: Geptanolimab
DrugBank: Geptanolimab (DB16417)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geptanolimab (GB226) 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Study: 37289335
Drug: High hemoglobin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hemoglobin target (11-13 g/dl) with darbepoetin alfa
Study: 37289335
Drug: Low hemoglobin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hemoglobin target (9-11 g/dl)
Study: 37289448
Drug: SB15 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB15 (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Study: 37289448
Drug: AFL (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFL (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Study: 37289451
Drug: Preoperative Stereotactic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Stereotactic Radiosurgery (SRS) at a median dose of 15 Gy in 1 fraction or 24 Gy in 3 fractions, delivered at a median of 2 days before resection.
Study: 37289541
Drug: Flu-IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu-IVIG treatment in IBV-infected patients (n = 62)
Study: 37289541
Drug: Flu-IVIG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu-IVIG treatment in IAV-infected patients (n = 50)
Study: 37289666
Drug: Reserve antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reserve antibiotic (Group 5, largely colistin-based)
Study: 37290035
Drug: Next-generation hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Next-generation hormonal agent (NHA)
Study: 37290102
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg IV)
Study: 37290102
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL normal saline IV)
Study: 37290104
Drug: RRSO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRSO with hormone use
Study: 37290104
Drug: RRSO without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RRSO without hormone use
Study: 37290461
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus cabozantinib (1200 mg intravenously every 3 weeks + 60 mg orally once daily)
Study: 37290947
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision rule (Marburg Heart Score combined with hs-cTnI-POCT, limit of detection 1.6 ng/L, cut-off value 3.8 ng/L)
Study: 37290967
Drug: Rituximab de-escalation
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab de-escalation (various regimens including discontinuations and switches to oral treatment)
Study: 37290996
Drug: INCB053914 (monotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Uzansertib (DB17571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB053914 (monotherapy)
Study: 37291651
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg/h continuous infusion after initial loading doses of 0.5 μg/kg for 15 min
Study: 37291651
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 μg/kg/h continuous infusion after initial loading doses of 0.75 μg/kg for 15 min
Study: 37291651
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg/h continuous infusion
Study: 37291651
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 μg/kg/h continuous infusion
Study: 37291651
Drug: Midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.03 mg/kg at anaesthesia induction
Study: 37291651
Drug: Dexmedetomidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.75 μg/kg
Study: 37291677
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IV imatinib twice daily for a maximum of seven days
Study: 37291677
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IV imatinib twice daily for a maximum of seven days in a subgroup of patients with high IL-6, TNFR1 and SP-D levels (n=20)
Study: 37291731
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of propofol (1.4 mg/kg TBW)
Study: 37291731
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of propofol (2.7 mg/kg TBW)
Study: 37292376
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (T-VEC) delivered by intralesional injection at 10
Study: 37293030
Drug: d-serine +
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-serine + AudRem (100 mg/kg)
Study: 37293067
Drug: Powder-based product
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-based product (potato maltodextrin) mixed with expressed breast milk, administered daily for 4 weeks
Study: 37293139
Drug: Guideline-directed medical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed medical therapy (co-GDMT) as per European Society of Cardiology guidelines
Study: 37294145
Drug: Multiple Electrolytes
Normalized name: Multiple Electrolytes Injection, Type 1, pH 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Electrolytes Solution (MES) (n = 351)
Study: 37294145
Drug: Multiple Electrolytes
Normalized name: Multiple Electrolytes Injection, Type 1, pH 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Electrolytes Solution (MES)
Study: 37294245
Drug: Semaglutide (glucagon-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (glucagon-like peptide-1 receptor agonist)
Study: 37294477
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 10 mg/kg every 6 hours, up to four doses per day
Study: 37294604
Drug: Adapted interactive
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted interactive obesity treatment approach for 6 months
Study: 37294609
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of 27 recommendations for intervention preparation and implementation in web-based games
Study: 37294843
Drug: Same-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day treatment (same-day TB testing with same-day TB treatment if TB diagnosed; same-day ART if TB not diagnosed)
Study: 37294843
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (initiating TB treatment within 7 days and delaying ART to day 7 if TB not diagnosed)
Study: 37294914
Drug: Eltrombopag (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (starting dose of 50 mg once daily to a maximum of 300 mg)
Study: 37295035
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies (NAb) transfer ratio (TR)
Study: 37295445
Drug: Lisocabtagene maraleucel
Normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10^6 cells, administered as a single intravenous infusion.
Study: 37295810
Drug: Adjunctive coiling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive coiling
Study: 37295836
Drug: Individualised duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised duration of antibiotic therapy (3 days after clinical improvement)
Study: 37295836
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration of antibiotic therapy (10 days)
Study: 37296922
Drug: Doxorubicin-ifosfamide chemotherapy
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin-ifosfamide chemotherapy and 5 × 5 Gy radiotherapy
Study: 37296982
Drug: 5-fluorouracil-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil-based chemotherapy (e.g., FOLFIRINOX)
Study: 37296982
Drug: Gemcitabine-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-based chemotherapy (e.g., gemcitabine/nab-paclitaxel)
Study: 37300484
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy for thyroid cancer
Study: 37300888
Drug: UR without
Approvals — FDA: no, EMA: no, PMDA: no
Description: UR without adjuvant chemotherapy
Study: 37300888
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival in UR without adjuvant chemotherapy
Study: 37301468
Drug: HPV ECHO+
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV ECHO+ (AAT to providers plus recall notices to vaccine-declining parents)
Study: 37301552
Drug: 4-week no
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week no manual therapy period
Study: 37301885
Drug: Neo-T therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-T therapy with lymphodepletion
Study: 37301885
Drug: Neo-T therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-T therapy without lymphodepletion
Study: 37302348
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving active cancer therapy
Study: 37302449
Drug: CurQD (curcumin-QingDai)
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: CurQD (curcumin-QingDai) 3 g/d for 8 weeks
Study: 37302533
Drug: Psilocybin-assisted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin-assisted group therapy (25 mg high-dose session)
Study: 37302963
Drug: Mini-dose esketamine-dexmedetomidine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mini-dose esketamine-dexmedetomidine combination
Study: 37302963
Drug: Patient-controlled sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sufentanil analgesia (4 μg kg)
Study: 37303003
Drug: BIA method
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA method for calculating CM dose
Study: 37303003
Drug: TBW method
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBW method for calculating CM dose
Study: 37303683
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel and rt-PA intravenous thrombolytic therapy
Study: 37304432
Drug: Fluvoxamine (FLV)
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine (FLV) treatment for 2 months
Study: 37304846
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron and folic acid (WIFA) supplementation and menstrual hygiene management (MHM) support for girls
Study: 37305080
Drug: Starch thickened
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch thickened formula with reduced lactose content, probiotics and prebiotics, administered for 30 days.
Study: 37305429
Drug: Pioglitazone hydrochloride
Normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone hydrochloride and metformin hydrochloride
Study: 37305429
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride
Study: 37306039
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy after 1-3 months of DAPT
Study: 37306107
Drug: Palbociclib 125
Normalized name: palbociclib 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 125 mg orally on Days 1-21 and ganitumab 18 mg/kg intravenously on Days 1 and 15 of a 28-day cycle.
Study: 37306107
Drug: Palbociclib 100
Normalized name: palbociclib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib 100 mg daily for 21 days (after dose reduction due to DLTs).
Study: 37306128
Drug: Pill coverage
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Covera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill coverage
Study: 37306288
Drug: BAY1128688 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 (3, 30, or 90 mg once daily or 60 mg twice daily for 14 days)
Study: 37306288
Drug: BAY1128688 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1128688 (60 mg once or twice daily for 28 days)
Study: 37306874
Drug: Seeking Safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seeking Safety (integrated treatment for gambling and PTSD)
Study: 37306874
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Pathological Gambling (for gambling alone)
Study: 37307001
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg orally once a day for 12 weeks
Study: 37307005
Drug: Add-on Rehmannia-6-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on Rehmannia-6-based Chinese medicine treatment for 48 weeks
Study: 37307005
Drug: Add-on Rehmannia-6-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on Rehmannia-6-based Chinese medicine treatment
Study: 37307232
Drug: Dexmedetomidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.6 μg kg -1 bolus followed by 0.4 μg kg -1 h -1 maintenance until dural closure)
Study: 37307514
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus Ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by Nivolumab 3 mg/kg once every 2 weeks for ≤24 months
Study: 37307514
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus Ipilimumab followed by Nivolumab monotherapy
Study: 37307528
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg q.d.)
Study: 37307844
Drug: Inoculation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation with 10 50% tissue culture infectious dose of pre-alpha wild-type SARS-CoV-2 (Asp614Gly) by intranasal drops.
Study: 37308133
Drug: Antibiotics (C1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (C1 group)
Study: 37308133
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (C2 group)
Study: 37308251
Drug: Y-2 sublingual
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-2 sublingual tablet
Study: 37308342
Drug: Dasatinib 50
Normalized name: dasatinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 50 mg daily
Study: 37308396
Drug: cfDNA level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: cfDNA level at diagnosis ≥ or <30 ng/mL and presence or not of KRAS-mutated ctDNA at D28
Study: 37308490
Drug: JMT101 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: JMT101 plus osimertinib 160 mg
Study: 37308679
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for SUD
Study: 37308751
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of once-weekly insulin icodec
Study: 37308751
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose of once-weekly insulin icodec
Study: 37308751
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of once-daily insulin glargine U100
Study: 37308751
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose of once-daily insulin glargine U100
Study: 37308905
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid infusion group (Ringer's lactate solution, maintaining PPV within 6-9%)
Study: 37308905
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid infusion group (maintaining PPV within 13-16%)